Sunitinib, sorafenib and other systemic noncytotoxic kidney cancer therapies can and should be administered by urologists.
Department of Surgery, University of Toronto and the Division of Urology, Sunnybrook Health Sciences Centre, Toronto, Ont.
Laurence
L
Klotz